Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Goldberg

Showing results (951-960 of 1,004) with videos related to

Pageof 101
Sort By:
Lancet (London, England)|December 18, 2015
Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 studyMartin Dreyling, Wojciech Jurczak, Mats Jerkeman, et al.
Lancet (London, England)|August 13, 2021
Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 studySaad Z Usmani, Alfred L Garfall, Niels W C J van de Donk, et al.
Leukemia & Lymphoma|January 8, 2015
Phase I dose escalation study of lestaurtinib in patients with myelofibrosisElizabeth O Hexner, John Mascarenhas, Josef Prchal, et al.
Haematologica|May 30, 2024
Prognostic impact of 'multi-hit' <i>versus</i> 'single-hit' <i>TP53</i> alteration in patients with acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic DiseasesTalha Badar, Ahmad Nanaa, Ehab Atallah, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 10, 2022
Patient Perceptions Regarding Ciltacabtagene Autoleucel Treatment: Qualitative Evidence From Interviews With Patients With Relapsed/Refractory Multiple Myeloma in the CARTITUDE-1 StudyAdam D Cohen, Parameswaran Hari, Myo Htut, et al.
Journal of Viral Hepatitis|March 7, 2018
Hepatitis C: The beginning of the end-key elements for successful European and national strategies to eliminate HCV in EuropeG V Papatheodoridis, A Hatzakis, E Cholongitas, et al.
The New England Journal of Medicine|December 12, 2022
Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody for Multiple MyelomaAjai Chari, Monique C Minnema, Jesus G Berdeja, et al.
Molecular Cancer Therapeutics|February 7, 2024
Trastuzumab-MMAU Antibody-Auristatin Conjugates: Valine-Glucoserine Linker with Stabilized Maleimide Conjugation Improves In Vivo Efficacy and TolerabilityShalom D Goldberg, Tero Satomaa, Olulanu Aina, et al.
Bone Marrow Transplantation|April 28, 2022
Low-dose unfractionated heparin prophylaxis is a safe strategy for the prevention of hepatic sinusoidal obstruction syndrome after myeloablative adult allogenic stem cell transplantMaria Sola, Valkal Bhatt, Meighan Palazzo, et al.
Blood|November 8, 2014
High day 28 ST2 levels predict for acute graft-versus-host disease and transplant-related mortality after cord blood transplantationDoris M Ponce, Patrick Hilden, Christen Mumaw, et al.
Pageof 101

Showing results (951-960 of 1,004) with videos related to

Sort By:
Pageof 101
Lancet (London, England)|December 18, 2015
Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 studyMartin Dreyling, Wojciech Jurczak, Mats Jerkeman, et al.
Lancet (London, England)|August 13, 2021
Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 studySaad Z Usmani, Alfred L Garfall, Niels W C J van de Donk, et al.
Leukemia & Lymphoma|January 8, 2015
Phase I dose escalation study of lestaurtinib in patients with myelofibrosisElizabeth O Hexner, John Mascarenhas, Josef Prchal, et al.
Haematologica|May 30, 2024
Prognostic impact of 'multi-hit' <i>versus</i> 'single-hit' <i>TP53</i> alteration in patients with acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic DiseasesTalha Badar, Ahmad Nanaa, Ehab Atallah, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 10, 2022
Patient Perceptions Regarding Ciltacabtagene Autoleucel Treatment: Qualitative Evidence From Interviews With Patients With Relapsed/Refractory Multiple Myeloma in the CARTITUDE-1 StudyAdam D Cohen, Parameswaran Hari, Myo Htut, et al.
Journal of Viral Hepatitis|March 7, 2018
Hepatitis C: The beginning of the end-key elements for successful European and national strategies to eliminate HCV in EuropeG V Papatheodoridis, A Hatzakis, E Cholongitas, et al.
The New England Journal of Medicine|December 12, 2022
Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody for Multiple MyelomaAjai Chari, Monique C Minnema, Jesus G Berdeja, et al.
Molecular Cancer Therapeutics|February 7, 2024
Trastuzumab-MMAU Antibody-Auristatin Conjugates: Valine-Glucoserine Linker with Stabilized Maleimide Conjugation Improves In Vivo Efficacy and TolerabilityShalom D Goldberg, Tero Satomaa, Olulanu Aina, et al.
Bone Marrow Transplantation|April 28, 2022
Low-dose unfractionated heparin prophylaxis is a safe strategy for the prevention of hepatic sinusoidal obstruction syndrome after myeloablative adult allogenic stem cell transplantMaria Sola, Valkal Bhatt, Meighan Palazzo, et al.
Blood|November 8, 2014
High day 28 ST2 levels predict for acute graft-versus-host disease and transplant-related mortality after cord blood transplantationDoris M Ponce, Patrick Hilden, Christen Mumaw, et al.
Pageof 101